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Background/Aims: Helicobacter pylori eradication 
may facilitate the healing of iatrogenic ulcer after en-
doscopic resection of gastric neoplasm. This study in-
volved designing a randomized, double-blinded, place-
bo-controlled, multicenter trial, performed by the 
Korean College of Helicobacter and Upper Gastroin-
testinal Research and the Medical Research Collabo-
ration Center, Seoul National University Hospital. 
Methods: We intend to enroll up to 232 patients H.- 
pylori-positive patients who have gastric adenoma or 
early gastric cancer after endoscopic resection. The 
enrolled patients are being randomly allocated to the 
H.-pylori-eradication-plus-proton-pump-inhibitor group or 
the placebo-plus-proton-pump-inhibitor group based on 
their histology results and the size of the resected 
specimen. After random allocation, the iatrogenic ulcer 
size and stage are evaluated at 4- and 8-week fol-
low-ups (with a window of ±7 days). The primary end 
point is the healing rate of the ulcer by stage, and 
the secondary end point is the rate of ulcer size re-
duction, relief rate from ulcer-related symptoms, and 
adverse-event rates. Results: More than 90% of the 
target subjects have already been enrolled into the 
study and are receiving ongoing periodic monitoring 
by the Medical Research Collaboration Center. 
Conclusions: Completion of the study should reveal 
whether H. pylori eradication can facilitate the healing 
of ulcer after endoscopic resection in Korea. (Gut 
Liver 2010;4:514-517)
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INTRODUCTION
  Endoscopic resection has been widely applied to gastric 
neoplasm such as gastric adenoma or early gastric cancer 
(EGC) as a curative treatment modality.1 Since endo-
scopic submucosal dissection method has been intro-
duced, complete en-bloc resection has been possible in 
larger-sized tumor rather than conventional endoscopic 
mucosal resection, but resulted in large iatrogenic ulcer. 
Although proton pump inhibitor has been administered 
for 4-8 weeks for the healing of iatrogenic ulcer, delayed 
healing has been observed in some portion of large-sized 
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iatrogenic ulcer, especially by submucosal dissection me-
thod. 
  Helicobacter pylori (H. pylori) eradication has been re-
ported to accelerate the healing of peptic ulcer as well as 
to prevent the recurrence.2 H. pylori eradication can facili-
tate the healing process by improvement of micro-
circulation and expression of variable endogenous growth 
factors.3 In the same manner with peptic ulcer, H. pylori 
infection may inhibit healing of iatrogenic ulcer after en-
doscopic resection of gastric neoplasm. Furthermore, larger 
iatrogenic ulcer by submucosal dissection method could 
be affected in the process of healing by H. pylori infection. 
Although H. pylori eradication may facilitate the healing of 
iatrogenic ulcer after endoscopic resection, there is no 
well-planned and designed study. Several studies have re-
ported the effect of H. pylori eradication on iatrogenic ul-
cer, but had many limitations of nonplacebo-controlled 
trial, small sample size, small ulcer size, short-term fol-
low-up, high drop-out rate or eradication before endo-
scopic resection.4,5 
  This randomized, double-blinded, placebo-controlled, 
multicenter trial has been planned and designed to eluci-
date the accurate sample size with statistical power, and 
monitored periodically with Medical Research Collabora-
tion Center, Seoul National University Hospital. Over 
90% among planned enrollment has been completed, and 
follow-up is still ongoing. 
MATERIALS AND METHODS
1. Study subjects
  From September 2008, patients who were considered 
eligible for endoscopic resection for gastric neoplasm in-
cluding gastric adenoma or EGC have been enrolling from 
6 general hospitals. Inclusion criteria are as follows; age 
30-75 years, pathologically-confirmed gastric adenoma or 
EGC, tumor size 1-3 cm, EGC with differentiated histol-
ogy, confined to mucosa and without evidence of distant 
metastasis, positive H. pylori infection. 
  The presence of H. pylori infection is determined by his-
tologic examination with Wright-Giemsa stain on antrum 
lesser curvature and body lesser curvature, rapid urease 
test on antrum or urea breath test. H. pylori infection is 
defined as the cases with positive results on at least one 
test among the three tests. 
  Exclusion criteria are as follows; piecemeal endoscopic 
resection, positive tumor at resection margin in patho-
logical mapping, history of medication such as proton 
pump inhibitor (PPI), H2 receptor antagonist (H2RA), su-
cralfate, bismuth, prostaglandin within 2 weeks of enroll-
ment, malignancy within 5 years of enrollment, current 
medication such as COX inhibitor, nonsteroidal anti-in-
flammatory drugs, aspirin, steroid, anticoagulants, an-
ti-platelet agents, history of gastric surgery, serious com-
plication with endoscopic resection, uncontrolled co-mor-
bid diseases, history of allergic reaction to antibiotics or 
PPI. The Institutional Review Boards of the six hospitals 
approved the study protocol and all participants provided 
written informed consents for the study. 
2. Sample size
  Previous studies reported that the healing rate of iatro-
genic ulcer was 70-85% in 8 weeks with 4 week-PPI 
treatment.4-7 Based on these results, the required sample 
size was 97 patients for each arm on assumption of 75% 
healing rate in placebo arm and 90% in eradication when 
the significance level was defined at 5% and power at 
80%. The patients for each arm should be acquired to 
116 when the expected drop-out rate fixed 20% due to 
follow-up loss or protocol violation. 
3. Endoscopic resection
  Endoscopic resection included conventional endoscopic 
mucosal resection (EMR) such as strip biopsy method, 
EMR using cap, EMR with precutting and snare, or endo-
scopic submucosal dissection. After endoscopic resection, 
removed specimen was smoothed and fixed with 10% 
formalin. Pathological mapping was conducted at 2 mm 
thickness, and complete en-bloc resection was defined as 
negative tumor from lateral and vertical resection margin 
in one piece at pathological mapping. Ulcer size was cal-
culated by multiplying the maximal diameter by the per-
pendicular diameter of specimen, and tumor size equally. 
4. Randomization and blinding
  At the day and next day of endoscopic resection, intra-
venous PPI is administered to prevent immediate compli-
cations such as bleeding or perforation. Patients satisfying 
the inclusion and exclusion criteria are stratified by two 
strata such as maximal diameter of ulcer on specimen (3 
cm and more vs less than 3 cm) and pathologic diagnosis 
(EGC vs adenoma), and randomly allocated to eradication 
and placebo arms with random permuted block design by 
web-based randomization program in Medical Research 
Collaboration Center. At 3rd day of endoscopic resection, 
patients in the eradication arm take lansoprazole 30 mg 
twice a day, amoxicillin 1,000 mg twice a day, and clari-
thromycin 500 mg twice a day for 1 week, and patients in 
the placebo arm take lansoprazole and two placebos of 
amoxicillin and clarithromycin twice a day for 1 week. 
After 1 week of eradication, all patients take only lanso-
prazole 30 mg a day for 3 weeks. Patients are instructed 
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Table 1. Clinical-Symptom Scoring
Grade Severity
None (0) Without any symptom
Mild (1) Minimal epigastric symptom
Moderate (2) Epigastric symptom without disruption of 
daily living activity
Severe (3) Epigastric symptom with disruption of daily 
living activity
not to take any other medications that may affect ulcer 
healing such as PPI, H2RA, bismuth, or sucralfate. 
Intermittent rescue antacid is allowed to relieve ulcer-in-
duced pain. 
  Medication package including amoxicillin, clarithro-
mycin and lansoprazole is contained in one bottle. 
Placebo is same in size and color with amoxicillin or 
clarithromycin. Medication is packed and labeled, and in-
formation of medication is sealed up according to ran-
domization by Medical Research Collaboration Center, 
Seoul National University Hospital. 
5. End point and follow-up endoscopy
  The primary endpoint for the study is iatrogenic ulcer 
healing rates by changes in stage, and the secondary end-
point is the reduction ratio of ulcer size, clinical symptom 
improvement rate and adverse event rates. Clinical visits 
are held at 2, 4, and 8 weeks after randomization. At 4 
and 8 weeks, follow-up endoscopy is performed to eval-
uate iatrogenic ulcer healing and H. pylori eradication. 
Iatrogenic ulcer healing is assessed by measuring changes 
in both ulcer stage and ulcer size in follow-up endoscopy. 
Ulcer stage is assessed using a six-stage system by Sakita 
and Fukutomi: active (A1, A2), healing (H1, H2) and scar 
(S1, S2) stages.8 Ulcer reduction ratio is determined by 
the ratio of initial ulcer size versus follow-up ulcer size at 
4 and 8 weeks. The primary endpoint is evaluated from 
ulcer healing rate at 8 week-follow-up endoscopy.
  Clinical symptoms are evaluated at 2, 4 and 8 weeks af-
ter randomization. Abdominal pain, epigastric soreness, 
acid regurgitation, epigastric discomfort, epigastric full-
ness, nausea and/or vomiting, diarrhea, changes of taste, 
headache and/or dizziness were recorded using scoring 
system (Table 1). The score 0 or 1 is defined as sig-
nificant clinical symptom improvement. Compliance is 
evaluated by counting remained tablets, and patients who 
had taken less than 80% of prescribed medications are 
excluded from the per-protocol analysis. 
  H. pylori eradication is evaluated by urea breath test at 
8 weeks after randomization. Thirty-eight mg of 13C-urea 
powder dissolved in 50 mL of water is administered or-
ally, and the second breath sample is collected at 30 
minutes. A cut-off value of 4‰ is used. 
6. Statistical analysis 
  The intention-to-treat analysis will be preferentially 
conducted for the evaluation of primary and secondary 
endpoints for all randomized patients who received medi-
cation at least once. Per-protocol analysis will be per-
formed for patients who would complete study protocol 
without any significant protocol violation. Significant pro-
tocol violation included inappropriate inclusion/exclusion 
criteria, compliance less than 80%, taking other medi-
cations that affect ulcer healing, and interim discontinua-
tion of study. 
  Baseline characteristics are tested by the chi-square 
test, the Student t-test or the Mann-Whitney U-test. The 
changes in ulcer stage and ulcer reduction ratio are tested 
by the chi-square test and the Mann-Whitney U-test, 
respectively. Clinical symptom improvement and adverse 
event rates of both arms are compared using the 
chi-square test. p-value less than 0.05 will be considered 
to be statistically significant. Statistical analyses were per-
formed using SPSS for Windows (version 12.0; SPSS Inc., 
Chicago, IL, USA) and SAS (version 9.1; SAS Inc., Cary, 
NC, USA). 
RESULTS
  Approval to conduct the study was received from the 
Institutional Review Board at 6 nationwide hospitals. A 
total of 202 patients were enrolled into the study be-
tween September 2008 and August 2010 with ongoing 
enrollment and follow-up. Interim periodic monitoring 
was conducted to maintain appropriate enrollment and 
follow-up by Medical Research Collaboration Center, and 
queries during monitoring has been solved by investi-
gators. 
  Over 85% of among planned subjects has been com-
pleted, and the enrollment is expected to close in 
December 2010. 
DISCUSSION
  Although H. pylori eradication has been established in 
the treatment of peptic ulcer and reducing relapse of the 
disease, it has not been clarified that H. pylori eradication 
could facilitate healing of iatrogenic ulcer after endoscopic 
resection of gastric neoplasm. Since H. pylori eradication 
has not been considered to be inevitable in the manage-
ment of iatrogenic ulcer after endoscopic resection, it has 
not been accepted for general clinical practice. 
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  In early phase after endoscopic resection, healing of ia-
trogenic ulcer may be influenced by H. pylori infection as 
well as mechanical defect of gastric wall including mucosa 
and submucosa because H. pylori infection can interfere 
mucosal blood flow around the margin of iatrogenic ulcer, 
which results in delayed ulcer healing.9 But in late phase 
of iatrogenic ulcer healing, most of iatrogenic ulcers can 
heal better rather than pathologic peptic ulcer irrespective 
H. pylori infection because H. pylori itself is not the main 
cause of diseases. 
  Previous studies have reported that H. pylori eradication 
facilitated ulcer healing in 4 weeks after endoscopic re-
section, but not in 8 weeks.4,10,11 In one study, mean ulcer 
dimension was less than 2 cm2, which could heal com-
pletely and not have any difference of healing rate in 4 
weeks irrespective of H. pylori eradication.4 In this study, 
because most patients stratified by 3 cm in maximal di-
ameter of specimen had size over 3 cm, complete ulcer 
healing would not be achieved in 4 weeks and may have 
difference in ulcer reduction ratio. In 8 weeks after endo-
scopic resection, other studies has reported that there 
was not any difference in healing rate irrespective of H. 
pylori eradication, which may be influenced by long-
standing PPI treatment.10,11 In this study, because most 
initial ulcer size was larger than previous reports and PPI 
was administered for 3 weeks, there is a possibility of 
significant difference of ulcer reduction ratio after 8 
weeks. 
  The advantages of this study are prospective planned 
design by multicenters and Medical Research Collabora-
tion Center, large-scaled placebo controlled random-
ization, and accurate sample size calculation considering 
20% drop-out. Furthermore, regular monitoring of appro-
priate enrollment and follow-up by Medical Research 
Collaboration Center would maintain good clinical trial 
with adequate feedback. This study will have the stat-
istical power to demonstrate whether H. pylori eradication 
exerts any clinically relevant effect on accelerating healing 
of iatrogenic ulcer after endoscopic resection of gastric 
neoplasm. 
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